Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 232-107-5 | CAS number: 7787-20-4
Endpoint summary
Administrative data
Description of key information
Acute oral toxicity: Key study. Test method according to OECD 423, GLP study. The LD50 of the test item is higher than 2000 mg/kg body weight by oral route in the rat. The LD50 cut-off may be considered to be 5000 mg/kg body weight by oral route in the rat.
Acute oral toxicity: supporting study. Read across aproach. Based on the read-across approach from the analogue d-fenchone, the LD50 of l-fenchone is 6160 mg/kg body weight by oral route in the rat.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 13 February 2018 - 07 March 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source:In-Vivo Biosciences, Kodigehalli Village, Magadi Road, Bangalore, Code-29, Karnataka State
- Females nulliparous and non-pregnant: yes
- Age at study initiation: 9 to 11 weeks
- Weight at study initiation: 187.8 to 201.6 g
- Fasting period before study: overnight prior to dosing until 3-4 hours post-dosing
- Housing: Rats were housed individually in standard polysulfone cages (Size: approximately L 425 x B 266 x H 185 mm), with stainless steel top grill having facilities for pelleted food and drinking water in polycarbonate bottle. Additionally, polycarbonate rat huts were placed inside the cage as an enrichment object and were changed along with the cage once a week. Bedding: steam sterilized corn cob was used and changed once a week along with the cage.
- Diet (e.g. ad libitum): Ad libitum. Hypro Rat & Mice pellet feed, manufactured by Krishna Valley Agro Tech LLP, MIDC Kupwad block, Sangli, Maharashtra, was provided to animals.
- Water (e.g. ad libitum): Ad libitum. Deep bore-well water passed through activated charcoal filter and exposed to UV rays in Aquaguard on-line water filter-cum-purifier manufactured by Eureka Forbes Ltd, Mumbai 400 001, India, was provided to animals in polycarbonate bottles with stainless steel sipper tubes.
- Acclimation period: the animals were acclimatized for six days (G1-first treatment step) and for eight days (G1-second treatment step) before treatment.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 to 24ºC
- Humidity (%): 64 to 67%
- Air changes (per hr): 13.5 to 13.6 air changes/hour
- Photoperiod (hrs dark / hrs light): 12 hours light and 12 hours dark cycle.
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- MAXIMUM DOSE VOLUME APPLIED: 2.12 mL/kg (Calculated based on the density of the test item: 0.945 g/mL (as per TIDS and COA))
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: Available information suggests that mortality is unlikely at the highest starting dose level (2000 mg/kg body weight). Hence, the study is initiated with the starting dose of 2000 mg/kg body weight. - Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 6
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: At each step, the animals were observed five times on test day 1 (day of administration) i.e. at 30 minutes and four times at hourly intervals and once daily during days 2 to 15 post administration. The body weights were recorded on test day 1 (pre-administration), day 8 (7 days post administration) and day 15 (14 days post administration).
- Necropsy of survivors performed: yes. At termination, gross pathological findings were recorded and reported.
- Other examinations performed:
Observations included changes in skin and fur, eyes and mucous membranes, and also respiratory, circulatory, autonomic and central nervous systems and somatomotor activity and behaviour pattern. Attention was directed to the
observations of tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma and all observed clinical signs were recorded. - Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Key result
- Sex:
- female
- Dose descriptor:
- LD50 cut-off
- Effect level:
- 5 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No mortality occurred during the study.
- Clinical signs:
- No clinical sign was observed in rats treated with 2000 mg/kg body weight.
- Body weight:
- Normal gain in body weight was observed in all the rats treated with 2000 mg/kg body weight.
- Gross pathology:
- There were no gross pathological changes at necropsy.
- Interpretation of results:
- other: Not classified (CLP Regulation EC no. 1272/2008)
- Conclusions:
- The LD50 of the test item is higher than 2000 mg/kg body weight by oral route in the rat. The LD50 cut-off may be considered to be 5000 mg/kg body weight by oral route in the rat.
- Executive summary:
The acute oral toxicity of the test item has been tested in accordance with OECD Test Guideline 423, following GLP. 6 female Wistar rats divided in 2 groups were administered sequentially with test item by oral gavage. The first set of 3 female rats was given a single dose of 2000 mg/kg body weight. No mortality was observed at this dose level, so the second set of 3 female rats was treated at the same dose level. No mortality was observed at this dose level either. The body weight evolution of the animals remained normal during the study. No clinical signs were observed. The macroscopic examination of the animals at the end of the study did not reveal treatment related effects. The LD50 of the test item is higher than 2000 mg/kg body weight by oral route in the rat. As per OECD Test Guideline 423, the LD50 cut-off of the test item may be considered to be 5000 mg/kg body weight by oral route in the rat.
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Remarks:
- Method similar to OECD guideline 423, but no information on doses were reported. No GLP.
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Version / remarks:
- The assay was performed before publication of this guideline but it follows a similar methodology
- Deviations:
- yes
- Remarks:
- No information on tested doses
- GLP compliance:
- no
- Species:
- rat
- Strain:
- Osborne-Mendel
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: no data
- Age at study initiation: young adults rats
- Fasting period before study: 18 h
- Diet (e.g. ad libitum): Food was replaced in cages as soon as animals received their doses.
- Water (e.g. ad libitum): Ad libitum.
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Doses:
- no data
- No. of animals per sex per dose:
- 5 females and 5 males
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 2 weeks
- Necropsy of survivors performed: no specified
- Other examinations performed: clinical signs, body weight and time of death - Statistics:
- LD50 were computed by the method of Litchfield & Wilcoxon (1949).
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 6 160 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- >= 4 400 - <= 8 630
- Mortality:
- Death time: 4 hr-9 days
- Clinical signs:
- Depression, scrawny appearance, porphyrin-like deposit around eyes and nose for a week after treatment.
- Body weight:
- no data
- Gross pathology:
- no data
- Interpretation of results:
- other: Not classified (CLP Regulation EC no. 1272/2008)
- Conclusions:
- The LD50 of the test item is 6160 mg/kg body weight by oral route in the rat.
- Executive summary:
The acute oral toxicity of the test compound was tested following a method similar to OECD Test Guideline 423. Ten young adult Osborne-Mendel rats evenly divided by sex were administered by oral gavage.
Animals were observed for 2 weeks during which time the development of toxic signs was followed and time of death recorded. During first week after treatment, depression, scrawny appearance and porphyrin-like deposit around eyes and nose were observed. The acute oral LD50 of the test item was determined to be 6160 mg/kg bw (95% confidence limits: 4400 -8630 mg/kg bw)
- Endpoint:
- acute toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Justification for type of information:
- REPORTING FORMAT FOR THE ANALOGUE APPROACH
The analogue substance d-fenchone which shares the same functional groups with the substance l-fenchone also has comparable values for the relevant molecular properties.
See attached the reporting format. - Reason / purpose for cross-reference:
- read-across source
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 6 160 mg/kg bw
- Based on:
- other: Read across from an analogue
- 95% CL:
- >= 4 400 - <= 8 630
- Remarks on result:
- other: read-across from an analogue for which LD50 = 6160 mg/kg bw (95% confidence limits:4400-8630 ppm)
- Mortality:
- Death time: 4 hr-9 days
- Clinical signs:
- Depression, scrawny appearance, porphyrin-like deposit around eyes and nose for a week after treatment.
- Body weight:
- no data
- Gross pathology:
- no data
- Interpretation of results:
- other: Not classified (CLP Regulation EC no. 1272/2008)
- Conclusions:
- Based on the read-across approach from the analogue d-fenchone, the LD50 of l-fenchone is 6160 mg/kg body weight by oral route in the rat.
- Executive summary:
The acute oral toxicity of the test compound was tested following a method similar to OECD Test Guideline 423. Ten young adult Osborne-Mendel rats evenly divided by sex were administered by oral gavage.
Animals were observed for 2 weeks during which time the development of toxic signs was followed and time of death recorded. During first week after treatment, depression, scrawny appearance and porphyrin-like deposit around eyes and nose were observed. The acute oral LD50 of the test item was determined to be 6160 mg/kg bw (95% confidence limits: 4400 -8630 mg/kg bw). Based on these results, the read-across approach was applied and the LD50 of l-fenchone was determined to be 6160 mg/kg bw (95% confidence limits: 4400-8630 mg/kg bw).
Referenceopen allclose all
Table 1. Body weight, body weight change and pre-terminal deaths
Group and Dose (mg/kg body weight) |
Rat No. |
Sex |
Body weight (g) |
Day of Death (Time of Death) |
No. dead/ No. tested |
Pre-terminal deaths (%) |
|||||
Initial (Day 1) |
8thday |
Weight change (day 8 – Initial) |
15thday |
Weight change (day 15 – Initial) |
At Death |
||||||
G1 (FTS) 2000 (2.12 mL/kg *)
|
Rm8055 |
F |
196.2 |
203.9 |
7.7 |
215.0 |
18.8 |
NA |
NA |
0/3
|
0 |
Rm8056 |
F |
188.6 |
198.7 |
10.1 |
210.3 |
21.7 |
NA |
NA |
|||
Rm8057 |
F |
187.8 |
198.1 |
10.3 |
210.8 |
23.0 |
NA |
NA |
|||
G1 (STS) 2000 (2.12 mL/kg *)
|
Rm8058 |
F |
192.8 |
203.6 |
10.8 |
214.2 |
21.4 |
NA |
NA |
0/3
|
0 |
Rm8059 |
F |
188.5 |
199.7 |
11.2 |
211.6 |
23.1 |
NA |
NA |
|||
Rm8060 |
F |
201.6 |
210.9 |
9.3 |
222.5 |
20.9 |
NA |
NA |
|||
FTS: First Treatment Step; STS: Second Treatment Step
*: Calculated based on the density of the test item: 0.945 g/mL (as per TIDS and COA).
Table 2. Individual clinical signs, dose administration and necropsy findings
Group and Dose (mg/kg body weight) |
Date and time of administration |
Rat No. |
Sex |
Body weight (Day 1) |
Total volume administered (mL) |
Day of observation |
||||
Day 1 |
||||||||||
30 min |
1hour |
2 hours |
3 hours |
4 hours |
||||||
G1 (FTS) 2000 (2.12 mL/kg*) |
19 February 2018 and 09:55 AM to 09.57 AM |
Rm8055 |
F |
196.2 |
0.42 |
N |
N |
N |
N |
N |
Rm8056 |
F |
188.6 |
0.40 |
N |
N |
N |
N |
N |
||
Rm8057 |
F |
187.8 |
0.40 |
N |
N |
N |
N |
N |
||
Group and Dose (mg/kg body weight) |
Rat No. |
Sex |
Day of observation |
Necropsy Findings |
||||||||||||||
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
|||||
G1 (FTS) 2000 (2.12 mL/kg*) |
Rm8055 |
F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
NAD |
|
Rm8056 |
F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
NAD |
||
Rm8057 |
F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
NAD |
||
Group and Dose (mg/kg body weight) |
Date and time of administration |
Rat No. |
Sex |
Body weight (Day 1) |
Total volume administered (mL) |
Day of observation |
||||
Day 1 |
||||||||||
30 min |
1hour |
2 hours |
3 hours |
4 hours |
||||||
G1 (STS) 2000 (2.12 mL/kg*) |
21 February 2018 and 09.53 AM to 09.55 AM |
Rm8058 |
F |
192.8 |
0.41 |
N |
N |
N |
N |
N |
Rm8059 |
F |
188.5 |
0.40 |
N |
N |
N |
N |
N |
||
Rm8060 |
F |
201.6 |
0.43 |
N |
N |
N |
N |
N |
||
Group and Dose (mg/kg body weight) |
Rat No. |
Sex |
Day of observation |
Necropsy Findings |
||||||||||||||
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
|||||
G1 (STS) 2000 (2.12 mL/kg*) |
Rm8058 |
F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
NAD |
|
Rm8059 |
F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
NAD |
||
Rm8060 |
F |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
N |
NAD |
||
FTS: First Treatment Step; STS: Second Treatment Step; NAD: No Abnormality Detected
*: Calculated based on the density of the test item: 0.945 g/mL (as per TIDS and COA).
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 5 000 mg/kg bw
- Quality of whole database:
- Key study with Klimisch score = 1
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Acute oral toxicity: Key study. The acute oral toxicity of the test item has been tested in accordance with OECD Test Guideline 423, following GLP. 6 female Wistar rats divided in 2 groups were administered sequentially with test item by oral gavage.The first set of 3 female rats was given a single dose of 2000 mg/kg body weight. No mortality was observed at this dose level, so the second set of 3 female rats was treated at the same dose level. No mortality was observed at this dose level either. The body weight evolution of the animals remained normal during the study.No clinical signs were observed. The macroscopic examination of the animals at the end of the study did not reveal treatment related effects. The LD50 of the test item is higher than 2000 mg/kg body weight by oral route in the rat. As per OECD Test Guideline 423, the LD50 cut-off of the test item may be considered to be 5000 mg/kg body weight by oral route in the rat.
Acute oral toxicity: supporting study. Read across aproach. The acute oral toxicity of the test compound was tested following a method similar to OECD Test Guideline 423. Tenyoung adult Osborne-Mendel rats evenly divided by sexwere administered by oral gavage. Animals were observed for 2 weeks during which time the development of toxic signs was followed and time of death recorded. During first week after treatment, depression, scrawny appearance and porphyrin-like deposit around eyes and nose were observed. The acute oral LD50 of the test item was determined to be 6160 mg/kg bw (95% confidence limits: 4400 -8630 mg/kg bw). Based on these results, the read-across approach was applied and the LD50 of l-fenchone was determined to be 6160 mg/kg bw (95% confidence limits: 4400-8630 mg/kg bw).
Justification for classification or non-classification
Based on the available data, the substance is not classified for acute toxicity according to CLP Regulation (EC) no. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
